Is this small-cap growth stock a bargain after today’s results?

This small-cap stock just saw its earnings rise nearly 70% on last year.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

When we think of healthcare and pharmaceuticals, companies such as GlaxoSmithKline and AstraZeneca generally spring to mind. But what about animal health? Are there investment opportunities in this area?

Today, I’m running the rule over specialist firm ECO Animal Health (LSE: EAH), which has this morning released its full-year results for the year ended 31 March. The stock has performed well over the last two years, so can this run continue?

Business description  

ECO manufactures and supplies animal health products, specialising in the development and marketing of medicines for the control of disease in livestock and companion animals. The £400m market cap company has operations in the UK, Europe, North America, Latin America, Africa and the Middle East and the majority of its sales are in currencies other than sterling. The company’s flagship product is Aivlosin, an antibiotic that treats a range of diseases in pigs and poultry.
 
It has enjoyed a strong rise in profitability in recent years. For example, for the five-year period to 2016, revenue increased from £27.1m to £47.1m, a compound annual growth rate (CAGR) of a healthy 11.7%. The company’s operating margin ticked up steadily in this time, resulting in net profit rising from £1.59m to £6.04m, a CAGR of over 30%.
 
Unsurprisingly, with profitability rising significantly, the company’s share price has followed a similar trajectory, and over the last five years the stock has risen from around 230p to 600p, a gain of an impressive 161%.
 
So are there further gains to come? Let’s look at the full-year results for an insight.

FY2017 results

This morning’s figures certainly look impressive. Revenue for the year increased 30% to £61.4m, and adjusted EBITDA rose 54% to £17.1m. Earnings per share jumped to 16.4p from 9.7p last year and the company increased its dividend payout by 25% to 7.1p per share. Cash generated from operations rose to £13.1m and left the company with a cash balance of £21m at the end of the year.
 
Management sounded confident about the future, with Chairman Peter Lawrence commenting: “ECO has started the current year strongly with revenue ahead of the previous year. The business is robust with a sound, debt-free balance sheet and this, coupled with our strong cash generation, will allow us to capitalise on market opportunities as they arise. We look forward with confidence.” 

Valuation

So it appears to be enjoying strong momentum at present, but is the valuation attractive right now? 

Today’s earnings per share figure places the company on a trailing P/E ratio of a high 37.8. With analysts forecasting earnings of 17.3p per share for FY2018, the forward-looking P/E ratio is a lofty 35.8. At that valuation, I’m not seeing a huge amount of value if I’m honest. The company’s growth certainly looks appealing, however the P/E ratio is just a little too high to interest me right now and doesn’t leave much room for error. For this reason, I’ll keep ECO Animal Health on my watchlist for now and monitor the stock for a pull-back in the share price.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Edward Sheldon owns shares in GlaxoSmithKline. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

The flag of the United States of America flying in front of the Capitol building
Investing Articles

Where will the S&P 500 go in 2025?

The world's biggest economy and the S&P 500 index have been flying this year. Paul Summers ponders whether there are…

Read more »

Passive income text with pin graph chart on business table
Dividend Shares

How to invest £20,000 in 2025 to generate safe passive income

It’s easy to generate passive income from the stock market today. Here’s how Edward Sheldon thinks investors should build an…

Read more »

Runner standing at the starting point with 2025 year for starting in new year 2025 to achieve business planing and success concept.
Investing Articles

Could the FTSE 100 hit 9,000 in 2025?

The FTSE 100 has lagged other indexes over the last year. But some commentators believe 2025 could be a stellar…

Read more »

Investing Articles

Why selling cars could drive the Amazon share price higher in 2025

After outperforming the S&P 500 in 2024, Stephen Wright's looking at what could push the Amazon share price to greater…

Read more »

Pink 3D image of the numbers '2025' growing in size
Investing Articles

3 of the best British shares to consider buying for 2025

Looking for UK shares to think about buying next year? These three stocks have all been brilliant long-term investments but…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

5 crucial Warren Buffett investing habits and a stock to consider buying now

Here's a UK stock idea that looks like it's offering the kind of good value sought by US billionaire investor…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Investing Articles

2 legendary FTSE 250 shares I won’t touch with a bargepole in 2025

Roland Head looks at two household names and explains why these FTSE 250 shares are already on his list of…

Read more »

Investing Articles

Why I think the Barclays share price is still a bargain heading into 2025

Stephen Wright thinks a combination of dividends and share buybacks means the Barclays share price is still attractive, despite a…

Read more »